XP’s Vision One Builds Brazil’s Top Eye-Care Network
Brazil · Companies
Key Facts
—The play. XP’s private-equity fund has rolled up eye clinics into Vision One, now Brazil’s largest ophthalmology network.
—The scale. Vision One has about 65 clinics and hospitals across roughly 30 cities and 13 states, with about R$500 million (roughly US$98 million) in revenue.
—The build. The fund put about R$200 million (roughly US$39 million) into the CBV chain as its platform, then merged it with Grupo H.Olhos.
—The firepower. The FIP XP Private Equity fund raised about R$1.3 billion (roughly US$255 million) in February.
—The endgame. Managers aim to grow the network and take it public within two to three years.
One of Brazil’s biggest financial names is quietly assembling a business in an unlikely corner of health care: your eyes. XP Vision One has become the country’s largest eye-care network, built deal by deal by XP’s private-equity arm.
XP’s private-equity fund created Vision One by merging its CBV holding with Grupo H.Olhos, building a network with about R$500 million (roughly US$98 million) in revenue, as Brazil Journal reported.
A roll-up in a fragmented market
Brazil has more than 5,000 eye clinics and hospitals, most of them small and independently owned — a classic fragmented market ripe for consolidation. XP’s private-equity fund set out to change that.
It took control of the CBV chain, investing about R$200 million (roughly US$39 million) to use it as a platform, then merged it with Grupo H.Olhos to create Vision One.
The result is already the sector leader: about 65 clinics and hospitals spread across roughly 30 cities and 13 states, with revenue near R$500 million (roughly US$98 million) and more than 5% of the market — a large share in a business where no single player has ever dominated.
In a fragmented market, the customer base is split among many small providers, none of which has the power to set prices or standards on its own. That creates an opening for a well-funded buyer to acquire several of those small players, combine their operations, and capture efficiencies that none could achieve alone.
The strategy, known as a roll-up, has reshaped industries from veterinary clinics to dental chains in other countries, but it is still relatively new in Brazilian health care.
Why eye care
The logic is demographic and financial. Brazil performs only about three eye surgeries per 1,000 people a year, against roughly ten in the United States, so demand has room to grow as the population ages and cataract and vision treatments become more common.
For investors, eye care offers steady, cash-generative demand and procedures that can be standardized across a network — the kind of defensive, scalable niche private equity likes.
Ophthalmology also sits at a sweet spot in medicine: it combines high-volume routine consultations with a growing menu of surgical procedures that can be performed in outpatient settings. That means a network can generate revenue from everyday eye exams and glasses prescriptions while also booking higher-value surgeries.
Because many of these procedures are elective and paid for out of pocket or through private insurance, the business is less exposed to the reimbursement cycles that squeeze other parts of the health-care system.
Live Company IntelligenceXp Inc — the full investor dossier
Wall Street view
Valuation & profitability
Price & risk
$14.8052-wk high
$22.83
Revenue trend · 6y
Ownership
Dividend
The money and the plan
The buying power comes from the FIP XP Private Equity fund, which raised about R$1.3 billion (roughly US$255 million) in February and is run by Chu Kong, a veteran who founded TMG Capital in the 1990s and spent more than a decade at the investor Actis. The strategy is a familiar private-equity playbook: buy a platform company, bolt on smaller rivals to build scale, professionalize the operation, and then cash out.
In this case the intended exit is a stock-market listing within two to three years — the moment when a roll-up either proves its worth to public investors or does not.
A fund like FIP XP Private Equity pools money from institutional investors and wealthy individuals, then deploys it over several years into a handful of companies. The fund’s managers earn fees for running the portfolio and typically share in the profits once they return capital to investors.
The R$1.3 billion raised gives the team significant firepower not just for the eye-care platform but potentially for other health-care or service businesses that fit the same consolidation thesis.
Why it matters
The deal is a window into how Brazilian finance is moving into health-care consolidation, chasing fragmented sectors where scale can lift margins and quality. For patients, a larger network can bring standardized care and investment in equipment, but also more concentration in who provides it.
For the market, Vision One will be a test of whether these roll-ups can translate into a successful public company rather than just a bigger private one.
The move also reflects a broader shift in Brazil’s capital markets. For years, the country’s largest financial groups focused on banking, asset management, and trading.
Now they are increasingly using their balance sheets and fund-raising networks to build operating companies in sectors once dominated by family-owned businesses. If the Vision One listing succeeds, it could encourage similar plays in dermatology, diagnostic imaging, or other specialty-care segments that remain highly fragmented across the country.
What to watch
The next test is execution. Rolling up dozens of independent clinics is one thing; running them as a single, profitable network with consistent quality is another, and it is where many health-care roll-ups stumble.
Investors will watch whether Vision One can keep adding sites without diluting margins, and whether the promised stock-market listing arrives on schedule — the moment that will show whether the strategy created lasting value or merely size.
Another open question is how the network will handle the human side of consolidation. Independent clinic owners who sell to a larger group often stay on as managers or doctors, and keeping them engaged while imposing standardized processes is a delicate task.
The fund’s ability to retain talent and maintain clinical quality across dozens of locations will be as important as any financial metric. Finally, the broader economic backdrop matters: a stock-market listing within two to three years depends on investor appetite for health-care shares at that moment, something no manager can fully control.
Frequently Asked Questions
What is Vision One?
Brazil’s largest eye-care network, built by XP’s private-equity fund by merging the CBV and H.Olhos groups — about 65 clinics and hospitals and R$500 million (roughly US$98 million) in revenue.
Who is behind it?
XP’s private-equity arm, through the FIP XP Private Equity fund, which raised about R$1.3 billion (roughly US$255 million) in February.
Why eye care?
The market is large but fragmented and underpenetrated — Brazil performs far fewer eye surgeries per capita than the US — leaving room to grow.
LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.
Read More from The Rio Times